| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 18.7 | 53.0 |
| Profit before tax | -21.5 | 8.6 |
| Net income | -20.1 | 16.8 |
| EPS (diluted, $ a share) | $-0.32 | $0.27 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -64.8% |
|---|---|
| Operating margin | -108.8% |
10-Q filed with the SEC, NASDAQ: MGNX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Macrogenics Inc: key numbers
- Share price
- $2.17Close, Nov 16
- Market cap
- $139M
- Shares outstanding
- 63.91MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Macrogenics Inc
All →Macrogenics Investor Presentation
MacroGenics, Inc. made available an updated corporate presentation on its website and as an exhibit to its 8-K filing. The presentation provides updated clinical program details and strategic priorities for the company's therapeutic candidates. The filing serves as a Regulation FD disclosure to ensure the updated information is available to the public and investors.
Macrogenics Financial Results
MacroGenics reported third quarter 2026 financial results, highlighting a cash position of $287.7 million and a cash runway extending through 2028. The company achieved several clinical milestones, including completing Phase 1 dose escalation for MGC028 and dosing the first patient in the Phase 1 study of MGC030.
- Term
- Q3 2026
“MacroGenics has made significant progress over the past year. We have strengthened our business, sharpened our pipeline development priorities, delivered on key strategic objectives and generated approximately $290 million in non-dilutive capital over the past 12 months.”
Eric Risser, President and Chief Executive Officer
“Looking ahead, we believe MacroGenics is well positioned for a year of important milestones in 2027, with multiple opportunities to demonstrate the potential of our innovative pipeline while maintaining a disciplined approach to capital allocation.”
Eric Risser, President and Chief Executive Officer
Macrogenics Leadership Change
MacroGenics appointed Dr. Michael Vasconcelles and Dr. Emil Kuriakose to its Board of Directors, effective October 30, 2026, increasing the board size to eleven members. Both appointees are independent directors with extensive oncology drug development experience and will serve on the company's Science and Technology Committee.
Macrogenics Clinical Trial Data
MacroGenics announced positive interim Phase 1 data for MGC026, a B7-H3-directed antibody-drug conjugate, in patients with advanced solid tumors. The study showed a 27% best overall response rate in heavily pretreated SCCHN patients and a manageable safety profile with no treatment-related discontinuations in that cohort. Based on these results, the company plans to initiate a front-line combination study evaluating MGC026 with pembrolizumab.